Allogeneic SCT May Be Effective for Some With Advanced Cutaneous T Cell Lymphomas
the ONA take:
Allogeneic stem cell transplantation may result in long-term remissions in a subset of patients with advanced cutaneous T cell lymphomas (CTCL), a new study published online ahead of print in the journal Annals of Oncology has shown.
Because patients with advanced CTCL and large cell transformation are incurable with standard treatments, researchers from The University of Texas MD Anderson Cancer Center in Houston sought to evaluate the outcomes of patients with advanced CTCL undergoing allogeneic stem cell transplantation.
In the prospective case series, researchers report the outcomes of 47 patients with CTCL who underwent allogeneic stem cell transplantation after failure of standard therapy.
Results showed that 4-year overall survival was 51% and 4-year progression-free survival was 26%. Researchers found that 4-year progression-free survival was superior in patients who had leukemic Sézary Syndrome, a common variant of CTCL, compared with those who did not.
In regard to safety, the cumulative incidences of grades 2 to 4 acute graft-versus-host disease (GVHD) and chronic GVHD were 40% and 28%, respectively.
“Although post-SCT relapse rates are high, many patients respond to immunomodulation and achieve durable remissions,” the authors conclude.
Allogeneic stem cell transplantation may result in long-term remissions in a subset of patients with cutaneous T cell lymphomas.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|